SCHEDULE: Vanguard Reports 0% Hologic Stake After Internal Realignment

The Vanguard Group has amended its Schedule 13G for Hologic Inc., reporting 0% beneficial ownership following an internal realignment that shifts reporting to its subsidiaries.

Summary

• The Vanguard Group filed an Amendment No. 12 to its Schedule 13G for Hologic Inc. Common Stock.
• The filing reports 0% beneficial ownership of Hologic Inc. Common Stock by The Vanguard Group.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report their beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over the securities beneficially owned by these subsidiaries and/or business divisions.
• These subsidiaries and business divisions continue to pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Hologic Inc. as it primarily reflects an internal organizational and reporting change by The Vanguard Group, not a change in investment thesis or a significant shift in overall institutional ownership.

Future Outlook

NA

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that this filing reflects a common practice among large institutional investors like The Vanguard Group to adjust their internal reporting structures for compliance and operational efficiency. The disaggregated reporting, permitted by SEC guidance, allows individual subsidiaries or business units to report their holdings independently, which can provide more granular insight into specific fund strategies, though the aggregate institutional exposure to Hologic Inc. by Vanguard-affiliated entities may remain substantial.

Stakeholder Impact

• Shareholders of Hologic Inc. should understand that this filing does not indicate a divestment by Vanguard-managed funds, but rather a change in how Vanguard's various entities report their holdings. The overall exposure of Vanguard-affiliated funds to Hologic Inc. may remain unchanged, just reported differently.

Key Dates

Recommendation

This filing is a technical compliance update from The Vanguard Group regarding its beneficial ownership reporting for Hologic Inc., stemming from an internal realignment. It does not reflect a change in investment strategy or a divestment from Hologic Inc. by Vanguard-managed funds. Therefore, it provides no new fundamental information to warrant a change in investment recommendation for Hologic Inc. A 'hold' recommendation is appropriate as existing investment theses remain unaffected by this administrative change.

Keywords

Hologic Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Investor, Common Stock, Internal Realignment, Reporting Change